title: Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.
authors.affiliation: Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD Department of Internal Medicine, Montefiore Medical Center, Bronx, New York, NY, USA.
authors.forename: Andrew H
authors.initials: AH
authors.lastname: Lipsky
authors.affiliation: Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD.
authors.forename: Jay N
authors.initials: JN
authors.lastname: Lozier
authors.affiliation: Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD wiestnea@nhlbi.nih.gov.
authors.forename: Adrian
authors.initials: A
authors.lastname: Wiestner
mesh_terms: D006470:Hemorrhage; D006801:Humans; D015994:Incidence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D012307:Risk Factors
keywords: chronic lymphocytic leukemia; disorders of platelet function; laboratory hematology